Duke-NUS and T Cells Diagnostics team up to simplify T-cell analysis
SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its related know-how from Duke-NUS Medical School to develop point-of-care assays that could simplify the analysis of T-cell responses.
Point-of-care tests can be performed quickly and easily at the site of patient care, such as in clinics or hospitals, without the need of specialised lab equipment. They provide rapid results, helping doctors and researchers make timely decisions.
TCD was established in Singapore in 2021 as a spin-off from Duke-NUS by Professor Antonio Bertoletti, Assistant Professors Nina Le Bert and Anthony Tan from Duke-NUS' Emerging Infectious Diseases Programme. Developed based on the licensed IP and its related know-how, TCD's test kits precisely measure the amount of virus-specific T cells in clinical samples by stimulating biological samples—ranging from whole blood to nasal swabs and bronchoalveolar lavage fluids—with synthetic peptides. In response to the stimulation, the T cells release chemical signals called cytokines, which can be easily measured.
Assistant Professor Nina Le Bert, who is currently applying this technology in her research on samples from patients chronically infected with the Hepatitis B Virus, said: "We are impressed by the simplicity and performance of the test kit, which has allowed the testing of hundreds of patient samples with ease and precision. It is heartening to see that the interest in measuring T-cell responses induced by vaccination or infection is gaining traction as such knowledge empowers healthcare providers and researchers to better understand immune responses in patients, in turn driving innovations to improve patient care."
Mr Alessandro Sidoli, CEO of T Cell Diagnostics: "We are confident that the addition of this technology to our portfolio is a major step towards achieving our goal of using T cells as a diagnostic. Our team combines deep scientific expertise with a commitment to delivering reliable, high-quality results, ensuring that our partners can confidently advance their research and clinical goals. Whether you're exploring immune responses to viral infections, vaccination, or even cancer, TCD is your trusted partner in unlocking the power of T cell immunity."
TCD offers end-to-end solutions, including project management, expert consultations, and advanced research testing services. The main focus is on analysing virus-specific cellular immune responses, with a particular emphasis on infections such as HBV, HDV, Influenza, SARS-CoV-2, and Dengue.
By quantifying the number and function of antigen-specific T cells, TCD provides critical insights that can guide diagnosis, treatment, and vaccine development. Operating from a state-of-the-art BSL-2 laboratory in Singapore's Biopolis, TCD is strategically positioned to serve local, regional, and international clients.
Associate Professor Christopher Laing, Vice-Dean for Innovation and Entrepreneurship at Duke-NUS, said: "Innovation in science is not just about discovery—it's about turning knowledge into solutions that improve lives. Duke-NUS scientists are among the most entrepreneurial in Asia, and our culture of innovation is supportive of partnering with startups. Our collaboration with TCD exemplifies Duke-NUS' commitment to bridging academia and industry, accelerating groundbreaking discoveries from universities to patients and society."
About Duke-NUS Medical School
Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
13 hours ago
- Korea Herald
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62 nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile. IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care. At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN," said Prof. Barratt. "We're excited to see how the upcoming Phase 3 trials will further define its role." The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks.
Korea Herald
13 hours ago
- Korea Herald
Countdown Begins: Hi & Fi Asia-China 2025 To Unveil Industry Breakthroughs In 20 Days
SHANGHAI, June 5, 2025 /PRNewswire/ -- With just three weeks remaining, anticipation builds for Hi & Fi Asia-China 2025, Asia's premier trade platform for health ingredients and food innovation. The landmark event, taking place June 24-26 at Shanghai's National Exhibition and Convention Center (NECC), promises to deliver groundbreaking innovations, critical market insights, and unparalleled networking opportunities for the global food and nutrition industry. Awards Spotlight: Final Days for Fi Innovation Submissions The inaugural Fi Innovation Awards program enters its final submission phase, with the June 8 deadline fast approaching. Open to both exhibitors and non-exhibitors, the awards recognize excellence across three key categories: Fi Technology Innovation Awards Fi Health Innovation Awards Fi Sustainable Innovation Awards The Awards will be judged by an esteemed panel of industry experts, including Annie Liu (Innova Market Insights), Dr. Lei Li (Shanghai Jiao Tong University), Jianqiang Bao (Shanghai Food Additives Association), Dr. Vetamur Krishnakumar (Giract), Rusong Li (Solidaridad), and Tao Zhang (Daofoods). These distinguished judges bring decades of combined experience across health ingredients, food technology, and sustainable innovation. Global Knowledge Exchange: Bilingual Forum Lineup This year's conference program features four bilingual forums designed to bridge industry knowledge: Specialized Innovation Tour Innova Market Insights will lead the popular "Beauty Walk" tour, showcasing breakthrough nutricosmetic innovations from featured exhibitors including Givaudan (Booth 41F40) and Synceres Biosciences (Booth 21D45). Brazil Takes Important Stage The Brazil Theme Day on June 25 will highlight South America's growing influence in nutraceuticals. Enhanced International Attendee Program Recognizing growing global participation, organizers have expanded benefits for overseas visitors: Guide in China – A comprehensive digital handbook covering: Registration & Participation With over 500 exhibitors and 15,000 attendees expected, early registration is strongly encouraged. About Hi & Fi Asia-China Now in its 26th edition, Hi & Fi Asia-China is the definitive marketplace for food ingredients, health innovations and sustainable solutions in Asia. The event is organized by Informa Markets, a global leader in B2B events and digital services.
Korea Herald
a day ago
- Korea Herald
SYNC ROBOTIC Launches AI Robot Platform in Taiwan, Pioneering Physical AI in Smart Security and Inspection
TAIPEI, June 4, 2025 /PRNewswire/ -- SYNC ROBOTIC, a subsidiary of Foxlink Group, today launched Taiwan's first AI Robot Platform, marking a major step into the emerging field of Physical AI. The platform is designed to meet the fast-growing global demand for intelligent security and inspection solutions. SYNC ROBOTIC's platform combines advanced hardware with reinforcement learning, integrating technologies such as speech and visual recognition, vision-language models (VLM), simultaneous localization and mapping (SLAM), path planning, and human-aware obstacle avoidance. The solution enables high-performance autonomous patrols in various environments such as commercial buildings, retail complexes, factories, and public infrastructure, providing a safer, more efficient approach to security management. "The 'AI Robot Platform' solution represents a major leap for SYNC ROBOTIC in the realm of Physical AI, and a strategic milestone for Foxlink Group's evolution into smart manufacturing and services," said Freddy Kuo, Chairman of SYNC ROBOTIC. "We're not just building innovative security solutions. We're creating a secure, intelligent, and reliable robotic service foundation that empowers industries worldwide, boosting efficiency and minimizing risk while unlocking new commercial value." The demand for AI-powered robots in security and inspection is rapidly growing, driven by automation, intelligence, and labor efficiency. Market Research Future predicts the global inspection robot market will grow from US$4 billion in 2024 to nearly US$20 billion by 2030, at a CAGR of 16.8%. SYNC ROBOTIC's platform is Taiwan's first AI robot solution tailored for autonomous security patrols, operating 24/7 in high-risk or unattended environments. Equipped with precision sensors and advanced AI algorithms, it delivers real-time situational awareness, anomaly detection, and automatic alerts, enabling swift, autonomous responses with minimal human intervention. The solution adopts the NVIDIA Isaac GR00T N1 model to drive robot development, equipping the robots with efficient edge computing and real-time decision-making capabilities. The system supports versatile robotic forms such as quadrupeds, humanoids, or drones, performing round-the-clock patrols with autonomous navigation, recharging, and anomaly detection. Equipped with modular sensors and advanced AI, the robots can detect events like intrusions or fires and trigger real-time alerts, minimizing human exposure to hazardous environments. Initial deployments have demonstrated the solution can triple inspection coverage while minimizing human exposure to high-risk environments. For example, in offshore wind farms, AI-powered quadruped robots can reduce the need for workers to travel at sea, improving both safety and efficiency. SYNC ROBOTIC plans to scale globally, beginning with the U.S. market via Foxlink's security brand Luminys. Future applications will extend to smart manufacturing, climate modeling, media production, and customer service, positioning Taiwan as a key force in the global AI and automation ecosystem.
